<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183505</url>
  </required_header>
  <id_info>
    <org_study_id>AYPB-MDD-Ⅱb-1701</org_study_id>
    <secondary_id>2017ZX09304-020</secondary_id>
    <nct_id>NCT03183505</nct_id>
  </id_info>
  <brief_title>Comparison of Anyu Peibo With Placebo in Treatment of MDD，Ⅱb</brief_title>
  <official_title>Safety and Efficacy Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Ⅱb Stratified Randomized, Double-Blind, Placebo-Paralleled, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Su Zhou YiHua Biotechnology Co. LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Anyu Peibo Capsule
      comparing with placebo in the treatment of Chinese Patients with Depression. And to provide
      some scientific evidence for protocol designing in following phase Ⅲ clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Actual">November 29, 2018</completion_date>
  <primary_completion_date type="Actual">October 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of total score from baseline in MADRS scale</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate according to MADRS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission Rate according to MADRS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate according to HAMD-17</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission Rate according to HAMD-17</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Change of CGI (CGI-S, CGI-I) from baseline</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Change of total score from baseline in HAMA</measure>
    <time_frame>6 weeks</time_frame>
    <description>Hamilton Anxiety Rating Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Physical Examination</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AE</measure>
    <time_frame>6 weeks</time_frame>
    <description>Adverse Events</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory Examination</measure>
    <time_frame>6 weeks</time_frame>
    <description>Blood RT, Urinalysis, Hepatic function, Renal function, FBG, Lipid, CK, Thyroid Function Test and Serum-HCG(fertile women only)</description>
  </other_outcome>
  <other_outcome>
    <measure>the Change of ECG from baseline</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Anyu Peibo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anyu Peibo Capsule, oral, 0.8g twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo,oral, twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anyu Peibo</intervention_name>
    <description>Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper</description>
    <arm_group_label>Anyu Peibo</arm_group_label>
    <other_name>Anyu Peibo Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Capsule, twice per day, oral after breakfast and supper</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria
             of DSM-5, single episode or recurrent episode.

          -  The total score of MADRS is ≥24 in both screening visit and baseline visit.

          -  The total score of HAMD-17 is ≥18 and the first item (depressed mood) is ≥2 in both
             screening visit and baseline visit.

          -  CGI-S is ≥4 in both screening visit and baseline visit.

          -  The subject understands and consents to takes part in this clinical trials. The
             subjects should sign informed consent form.

        Exclusion Criteria:

          -  The subject has a suicide attempt within recent 1 year, or has a currently significant
             risk of suicide, or has a score ≥3 on item 3(suicide assessment) of the HAMD.

          -  The subject has a current psychiatric diagnosis other than depression.

          -  When the HAMD-17 score of baseline visit compares with the screening visit, the
             decreasing rate is ≥25%.

          -  Known hypersensitivity to Big Leaf Ju, or at least to two kinds of drugs.

          -  Any unstable cardiovascular, hepatic, renal, blood, endocrine, or other medical
             disease.

          -  Any neurological disease (such as Parkinson's Disease, cerebrovascular accident and
             epilepsy) or cerebral injury (traumatic or disease related).

          -  Had a history or a high risk related disease or medication of seizure disorder,except
             infantile febrile convulsion.

          -  Had a history of hyperthyroidism or hypothyroidism within recent 1 year and still
             taking medication.

          -  With psychotic symptoms.

          -  The subject has a history of mania episode, including manic, mixed, bipolar depression
             or rapid cycle attack.

          -  The subject has a current diagnosis of depression due to a somatic disease.

          -  The subject could not take medication or has a disease affecting drug absorption, such
             as active bowel disease, partial or total intestinal obstruction, or chronic diarrhea.

          -  Clinically significant electrocardiographic(ECG) abnormalities in screening visit.
             Such as QTc ≥450 ms in male or ≥470 ms in female; Sinus bradycardia and HR ≤ 50 bpm; Ⅲ
             atrioventricular block; atrial fibrillation, etc.

          -  Clinically significant abnormal laboratory values(eg. Routine blood value above or
             below 1.2 times of the normal range; urine WBC, RBC or protein ≥++; ALT or AST value
             above 1.5 times of clinical top-limit; BUN value above 1.2 times of top-limit; Cr
             value above normal top-limit; thyroid gland function index above or below 1.2 times of
             the normal range, Fasting plasma glucose value above 1.2 times of normal top-limit;
             blood fat value above 1.5 times of normal top-limit).

          -  The subject who used at least two different antidepressants with recommended dose and
             adequate duration (maximum dosage by at least 4 weeks according to label) treatment
             still had no respond.

          -  The subject uses antidepressant drug normally before 2 weeks of screening, and stops
             using psychotropic drug before randomization less than 7 half-life period (monoamine
             oxidase inhibitor: at least 2 weeks; fluoxetine: at least 1 month)

          -  The subject received light therapy within 2 weeks.

          -  The subject received ECT, trans-cranial magnetic stimulation, or other physics therapy
             within 3 months.

          -  The subject received systematic psychotherapy (interpersonal relationship,
             psychoanalytic therapy, or cognitive behavioral therapy) within 3 months or plan to
             use systematic psychotherapy during the study period.

          -  The subject has a history of substance abuse (including alcohol, drug or other
             psychoactive substance) within 1 year before screening.

          -  Women who were pregnant, breast-feeding, or serum-HCG(+) on screening; or planning to
             become pregnant within 3 months after kick-off of clinical trial.

          -  The subject has participated in a drug clinical trial within 1 month before screening.

          -  The investigator thinks the subject is unsuitable to enroll in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang LI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anding Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing HuiLongGuan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Mental Health Center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Mental Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Hospital of Jilin Province</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XI'AN Mental Health Center</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>January 19, 2019</last_update_submitted>
  <last_update_submitted_qc>January 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

